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Abstract
Cystic fibrosis (CF) is a genetic disease that hampers the lung function. Despite that the 
main defective gene has been deeply characterized, some relevant concerns still need 
to be resolved before considering gene therapy as a realistic medical choice. One of 
the major issues that need to be strongly considered in order to succeed in the search 
for an effective gene therapy approach for CF is the design of the appropriate genetic 
material to be delivered. Other relevant factors to take into consideration include the 
design of safe and effective gene delivery systems, the biological barriers that need to 
be overcome in order to reach the nucleus of the target cells, and the problems related 
to the design of a drug formulation suitable for lung delivery purposes. Furthermore, 
some problems related to the commercialization of gene therapy products also need 
to be resolved. In this chapter, we discuss the up-to-date strategies to overcome such 
hurdles in order for gene therapy to become a routine treatment modality for CF.
Keywords: cystic fibrosis, gene therapy, drug delivery, biological barriers, drug 
formulation
1. Introduction
Cystic fibrosis (CF) is a rare disease with low prevalence caused by the dysfunction of the 
transmembrane conductance regulatory gene (CFTR). The most prevalent CFTR mutation 
consists of a deletion of a phenylalanine at position 508 [1]. The disease presents a hetero-
geneous distribution in the world population being more frequent in Northern Europe. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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distribution, and reproduction in any medium, provided the original work is properly cited.
According to recent reports, in the European Union, 1 of every 2000–3000 newborns is 
affected by CF. In the USA, the incidence is 1 per 3500 births. In Asia, the predisposition to 
CF is low; however, there is evidence to show that this disease is severely underdiagnosed 
[2]. The basic characteristic of CF is the transport of defective ions in the apical membrane 
of most secretory cells, which leads to an altered secretion of mucus in the epithelium of 
the respiratory tract, the digestive tract, the pancreas, the liver, and the reproductive track 
[1]. The conventional treatments available on market, which include, among others, anti-
biotics, pancreatic enzyme supplements, high-fat diets, and even physiotherapy [3], afford 
the consequences derived from CFTR dysfunction and have significantly improved 
the mean life expectancy of patients affected by the disease up to 34 years [4]. However, 
their quality of life is severely compromised mainly due to side effects and interactions 
among such treatments [5]. Therefore, other therapeutic options such as gene therapy, in 
which the main goal is to restore the function of the mutated CFTR protein acting on the 
genetic cause of the problem, need to be considered. CFTR gene was cloned more than 
two decades ago, and the monogenic and autosomal recessive nature of CF disease means 
that the addition and expression of the corrected gene could reverse the underlying cause 
of the disease. Therefore, there is reasonable hope to consider gene therapy as a poten-
tial realistic medical option, and consequently, some clinical trials have been performed 
since 1993. However, despite the moderate optimism that emerged with the development 
of such clinical assays, there are still some hurdles to overcome before considering gene 
therapy a realistic medical option. Main concerns are related to the intrinsic properties 
of genetic materials, the development of safe and efficient gene delivery vectors able to 
deliver genetic materials to the nucleus of target cells, the design of a drug formulation 
suitable for pulmonary gene delivery applications, and the hurdles associated with the 
commercialization of such drugs (Figure 1).
Figure 1. Hurdles that gene therapy should overcome in order to reach clinical practice in the treatment of CF disease.
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In the next sections, we will analyze such barriers along with the most relevant approaches 
developed by the scientific community to circumvent them in order to cure CF with gene 
therapy.
2. Genetic material
2.1. Plasmid DNA
Bacterial plasmid DNA (pDNA) remains an interesting biomolecule for gene transfer, with sev-
eral promising reports and clinical trials in progress worldwide [6]. In CF, pDNA has been suc-
cessfully delivered by nonviral vectors to the sheep lung [7]. Additionally, when administered 
in multiple-dosage regimen, no loss of activity was observed [8]. In order to be produced in 
recombinant bacteria and to express their therapeutic gene of interest (GOI), pDNA needs a bac-
terial origin of replication sequence (bac-ORI). In addition, pDNA backbone includes a sequence 
with resistance to one/various antibiotics such as kanamycin, which allows to select the clone 
of bacteria transformed that expresses the plasmid. Finally, a eukaryotic promoter is needed to 
enhance GOI expression [9]. Usually, when pDNA reaches the nucleus of target cells, it remains 
in an episomal position, which means that it replicates independently from the host chromo-
somal DNA, avoiding the undesirable activation of oncogenic genes [10]. The main concerns of 
pDNA in gene therapy are related to safety issues. Classically, in eukaryotic cells, pDNA has 
been associated with the induction of undesired immune responses and secretion of proinflam-
matory cytokines [11]. For instance, a transient neutrophilic infiltration and an elevation in pro-
inflammatory cytokines have been reported in mouse lung [12]. Although the episomal nature 
of pDNA could be an interesting advantage, the transfection efficiency remains compromised 
mainly by the transient and relatively low gene expression. Additionally, the size of the plasmid, 
determined by the number of base pairs, jeopardizes transfection efficiency [13, 14].
2.2. Minicircle DNA
In order to overcome the previously mentioned disadvantages associated with the use of 
pDNA in gene therapy, small plasmidic cassettes known as minicircle DNAs (mcDNAs) have 
been recently developed [15]. Cameron and Scheleff first employed mcDNA terminology in 
1995. Nowadays, this technology offers a potential alternative to enhance both transfection 
efficiency and safety of gene delivery [14]. Basically, mcDNAs are circular constructors simi-
lar to pDNA but significantly smaller, since mcDNAs contain a minimal expression cassette, 
of a promoter, a transgene, and a polyadenylation, signal but are devoid of bacterial pDNA 
elements. Thus, mcDNA technology allows sustained transgene expression mainly due to 
a lower activation of nuclear transgene silencing mechanisms and reduced immunogenic 
responses in vivo [16, 17].
In the lung, some promising results have been obtained with the use of small plasmidic cas-
settes [18]. In fact, results of a Phase IIb double-blind clinical trial for CF have been recently 
reported. These trials were performed with a plasmid encoding CFTR gene and lacking CpG 
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bacterial region, known as pGM169 [8]. In such study, treated patients exhibited modest but 
significant improvements in lung function compared to placebo-treated ones during 1-year 
follow-up [19]. In any case, despite the optimism generated, there are still some concerns that 
need to be considered, such as the reproducibility of the results; the intensity of the response, 
probably conditioned by the degradation of formulation after aerosolization process; or the 
number of patients that received such treatment.
2.3. Genome editing tools
Both previously mentioned approaches based on pDNA and mcDNA technologies allow to 
restore the function of the mutated CFTR gene, with the addition of normal copies, but they 
do not correct the mutation at their local chromosomal location. However, genome editing 
tools based on zinc-finger nucleases (ZFNs), or transcription activator-like effector nucleases 
(TALENs), can specifically correct CFTR gene mutations at their natural chromosomal loca-
tion, and so, the corrected gene can remain under the control of its endogenous promoter [20].
ZFNs are synthetic restriction enzymes, which have three or more zinc-finger DNA-binding 
motifs linked to the FokI restriction enzyme that recognizes trinucleotides in a specific DNA 
sequence [21]. When FokI enzyme creates a double-strand break (DSB) near the mutation 
place, cellular DNA repair mechanisms are activated to maintain cell viability. In these condi-
tions, a donor DNA sequence with high 5′ and 3′ homology with the DNA sequence where 
DSB has been generated can be exogenously supplemented to enhance the correction of the 
mutation by homologous recombination (HR) mechanism. This genome editing tool has been 
successfully used in vitro to correct CFTRΔF508 mutation in both human bronchial epithelial 
cells [22] and CF-induced pluripotent stem (IPS) cells [23].
TALEN technology is very similar to ZFNs. These nucleases were originally characterized in 
Xanthomonas bacteria, in which TALEN proteins are secreted when Xanthomonas infect a wide 
variety of plants, thus activating genes that help to develop the pathogenesis. This genome 
editing tool also produces a DSB around the mutation site of the target gene and consequently 
induces cellular DNA repair mechanisms [24]. TALENs are considered as a more efficient and 
cost-effective alternative to ZFNs [25]. In the case of ZFNs, each finger module recognizes 
three to four bases of the DNA sequence. However, in the case of TALENs, gene recognition 
is mediated by a more specific mechanism, where each module of 33–35 amino acid targets a 
single nucleotide. This technology has been recently applied to correct CFTRΔF508 mutations 
in CF patient-specific IPS cells [26]. Overall, such study reported correction of patient-specific 
IPS cells in less than 3 months, which could allow rapid scaling up for future applications.
Clustered regularly interspaced short palindromic repeats (CRISPR) methodology, originally 
described as an adaptive immune response in archaea, follows the same rationale described 
for ZFNs and TALENs, but instead of protein domains, short RNA molecules are used to drive 
the required homology [27]. In this case, an endonuclease called Cas9 is guided by a single 
guide RNA (gRNA) to hybridize specifically with the mutated sequence in the DNA; then, 
as described for ZFNs and TALENs, the resulting DSB triggers cellular DNA repair mecha-
nism [28]. The main advantage of CRISPR technology is that it is an easy-to-synthesize cost-
effective tool that is able to correct more than one mutation at the same time, if multiple-gene 
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targeted sgRNAs are delivered to target cell along with the Cas9 protein, which makes it an 
excellent option [24]. CRISPR technology has been applied to repair CFTRΔF508 mutations in 
intestinal stem cell organoids of CF patients [29].
This study represents an interesting proof of concept for CFTRΔF508 correction by HR using 
CRISPR/Cas9 technology in primary adult stem cells derived from patients with a single-
gene hereditary defect and offers reasonable hope to be successfully applied to the lungs of 
patients affected by CF. However, some relevant concerns, mainly related to the frequency of 
undesirable off targets, still need to be resolved in order to reach clinical practice [19].
3. Vectors
One of the main concerns related to the clinical application of gene therapy is the design 
and development of safe and effective gene delivery vectors to introduce exogenous genetic 
material into the nucleus of target cells [30, 31]. In the absence of gene delivery vectors, naked 
genetic material is quickly degraded mainly by exogenous deoxyribonuclease enzymes, 
which clearly inhibit transfection efficiency [31]. Additionally, the negatively charged genetic 
material, mainly due to the phosphate groups, hampers the electrostatic interactions with 
cell membranes, which are negatively charged too. Therefore, the clinical application of gene 
therapy demands the design, characterization, and evaluation of efficient and safe carriers to 
mammalian cells.
3.1. Viral vectors
At present, viral-based carriers are the most appropriate from an effectiveness point of view. 
The natural evolution that viruses have undergone over many years has allowed them to 
face different intra- and extracellular barriers and, consequently, infect target cells with high 
efficiency.
In the CF field, a wide variety of viral-based vectors has been developed in clinical trials. The 
first one was performed in 1993 with adenovirus in three patients, where partial correction of 
the chloride transport in nasal epithelium was observed [32]. Some of the main advantages 
of adenoviruses include their non integrating nature and their natural tropism for the lung. 
However, despite such favorable properties, and the high transduction efficiency observed in 
most tissues, gene expression usually remains transient, and these viruses can induce strong 
immune and inflammatory responses in a dose-dependent manner, which clearly brings up 
safety issues and, therefore, limits their application in the clinical practice [8].
Initial clinical trials performed with adenovirus allowed the development of adeno-associated 
viruses (AAV), which have interesting characteristics for their application in gene therapy, 
such as broad tissue tropism, high transduction efficieny, and persistent episomal expres-
sion, which can last for years, even though it is a non integrating vector [33, 34]. In addition, 
recombinant AAV vectors have been shown to be safe in several clinical trials, as they are not 
related to any known human disease. However, these vectors also present relevant limita-
tions, the main one being their low capacity to load genetic material (<5 kb) [35]. Between 
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1999 and 2007, six clinical trials were conducted with these kinds of vectors in CF [8]. Phase I 
clinical trials demonstrated that a single-dose administration of AAV in the respiratory tract 
of patients affected by CF was safe and well tolerated [36]. Nevertheless, subsequent studies, 
with repeated doses in more patients, did not report significant improvement in lung function 
[37]. This lack of efficacy was mainly attributed to the low DNA loading capacity of AAV, 
which prevented loading the 4.7 kb of the CFTR gene [8]. In addition, AAV capsid-specific 
immune responses limited repeated administrations in patients [8]. Nowadays, some inter-
esting strategies are being developed in order to minimize adaptive immune responses after 
repeated administration, such as the design of hybrid AAV capsids or the removal of CpG 
bacterial regions from AAV vectors [38, 39].
Lentiviruses have an integrative nature and have shown long-term and stable transgene 
expression when administered in the respiratory tract of mice, which minimizes the need 
for repeated administration [40]. Additionally, the packaging of full-length CFTR gene and 
promoters is not limited by size. Therefore, nowadays they are considered promising vectors 
for the treatment of CF [41]. However, in order to consider its use in clinical practice, some 
concerns still need to be resolved, such as the scaling in the production of these vectors and 
the control of the place where the transgene is inserted into the genome of the pulmonary 
cells, which could increase the tumorigenicity potential of such viral vectors due to random 
integration [20]. Consequently, such viral vectors could be more suitable for ex vivo than 
for in vivo therapy. In any case, a promising study in three newborn CF pigs has recently 
shown that 2 weeks after lentiviral delivery by aerosolization, the anion channel defect can be 
corrected in a large animal CF model [42]. Other recent studies assessed with pseudotyped 
lentivirus vectors in both murine lungs and human air-liquid interface cultures showed that 
preexisting and acquired immune responses do not interfere with vector efficacy [43]. In such 
study, at least 14% of the airway cells were transduced. Interestingly, toxicological results, 
notably the integration site profile showing absence of integration near oncogenic loci, sup-
port further progression toward clinical trials.
3.2. Nonviral vectors
Although the use of viral-based vectors in clinical trials still predominates over that of nonviral 
vectors, in recent years, there has been a notable increase in preclinical studies using 
nonviral vectors [44]. The reason is that these systems represent a safer, cheaper, and easier 
to produce alternative to viral-based vectors [18]. The main advantages of nonviral vectors 
include, among others, the ability to produce them on a large scale with high reproducibility 
and low cost; their relative stability after storage; the possibility of multiple-dose regimen 
administration due to their low immunogenicity; their high capacity to carry genetic mate-
rial, independently of the size [45]; as well as the possibility to modify them chemically in 
order to regulate important physicochemical parameters, such as size, charge, morphol-
ogy, or polydispersion, which clearly influence their final biological properties. All these 
important advantages have raised the interest of the scientific community to develop new 
biocompatible materials of different structures, compositions, sizes, and characteristics to 
transport therapeutic genes into specific organs or cells, overcoming the different extra- and 
intracellular barriers [46].
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Within the large variety of nonviral vectors developed, most of them are based on peptides as 
well as on cationic lipids and polymers, which form the corresponding complexes (polyplexes 
and lipoplexes) after electrostatic binding with DNA [47]. The resulting complexes protect 
nucleic acids from enzymatic degradation and facilitate cellular uptake by interactions with 
the cytoplasmic membrane [48]. The PEG-CK30 peptide, due to its low immunogenicity and 
its ability to be endocytosed by cells, is one of the most widely used, although the formulation 
must be optimized to allow its administration in aerosol form to reach the lungs [49].
Regarding cationic polymers, polyethylenimine (PEI) is one of the most used, since its chemi-
cal structure can be easily modified to increase the efficiency of transfection, for example, by 
incorporating lactose (Lac-PEI) to improve intracellular trafficking [50]. However, PEI has not 
yet been used in any clinical trial. The main limitation lies in the difficulty that exists to pre-
pare PEI polyplexes at high DNA concentrations [49]. One of the most promising strategies 
that have been used to circumvent this problem is the use of ultrafiltration methods, through 
which PEI/DNA concentrates are prepared.
In the case of cationic lipids, some of the most widely used to develop nonviral formulations 
in the CF field are N-[1-(2,3-dioleyloxy) propyl]-N, N, N-trimethylammonium, dioleoylphos-
phatidyl ethanolamine, and dioleoyl trimethyl ammonium [51]. However, currently, the most 
promising nonviral vector in CF clinical trials is based on the cationic lipid GL6TA, which was 
synthesized to prevent DNA degradation in the lysosome and to be stable after pulmonary 
administration by aerosolization [8, 51]. In 2011, a preclinical comparative study of the use of 
PEI, PEG-CK30, or GL67A nonviral vectors in aerosols demonstrated that this last formula-
tion was the best one to transport DNA to sheep’s lungs [7]. Moreover, in an extensive pre-
clinical study performed in 2014 [52], it was corroborated that the formulation based on the 
lipid GL67A, which had already been used for 15 years in CF clinical trials, was still suitable 
for administration in multiple-dose regimen, without any observed loss of activity [8].
4. Biological barriers
In order to reach the nucleus of target cells and initiate transgene expression, the genetic 
material must overcome some extracellular and intracellular barriers, which will be discussed 
in this section, along with the most relevant strategies that have been developed to make the 
transfection process more efficient.
4.1. Extracellular barriers
Even though intravenous injection is one of the most commonly used administration routes, 
especially for delivering genetic cargo into cancerous cells, some barriers still hamper its use 
in clinical practice, particularly in the CF disease [53]. First of all, the genetic material needs 
to be protected against extracellular enzymatic digestion, since DNA is quickly degraded 
when administered alone. To avoid such quick degradation, nonviral vectors based on both 
positively charged lipids and polymers offer the possibility to condense on their surface 
the genetic material by electrostatic interactions and minimize such undesirable effect [54]. 
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However, the final positive charge of polyplexes or lipoplexes can interact in a nonspecific 
way, not only with target cell membranes but also with other negatively charged compo-
nents such as serum proteins that jeopardize transfection efficiency [55]. These interactions 
could result in the formation of aggregates that classically are eliminated from the blood by 
the reticuloendothelial system. Interestingly, the incorporation of polyethylene glycol (PEG) 
motifs into the formulation of some nonviral carriers enhances the stability of complexes, 
since the highly hydrophobic nature of PEG chains creates a steric barrier to prevent both 
aggregation of complexes in blood circulation and extracellular enzymatic degradation by 
nucleases [55]. In any case, other relevant aspects related with both the length and the degree 
of PEGylation should be also considered, as they can also decrease DNA condensation effi-
ciency with nanoparticles [56]. In addition to PEG, other polymers with hydrophobic nature 
such as poly(4-acryloylmorpholine) or poly(N,N-dimethylacrylamide) have recently emerged 
as interesting and promising alternatives to compensate or ameliorate the negative effects 
associated with PEGylation [57].
Since intravenous injections present relevant hurdles that hamper the delivery of genetic 
material into target lung cells, local administration into the lung seems to be a reasonable 
alternative. In this case, the presence of mucus and the clearance mechanism are the most rel-
evant barriers to overcome [58]. To avoid such barriers associated with pulmonary adminis-
tration, other interesting noninvasive routes of administration, such as intranasal instillation, 
can be used to target lung cells. Nevertheless, the main problem is the low amount of genetic 
material that can be administered by the intranasal route. From a technical point of view, 
aerosolized nonviral vector/DNA complexes, carefully designed for inhalation in combina-
tion with appropriate excipients to enhance both particle flow and aerodynamic diameter, 
could be an interesting option since they are needle-free systems able to deliver locally high 
cargo concentrations [53].
To circumvent the diffusion of complexes into lung cells due to unspecific interactions with 
the biopolymer network of the mucus, some mucolytic agents that hydrolyze mucins can be 
added [58]. Other strategies include the incorporation of N-acetylcysteine to reduce disulfide 
bridges between the subunits of mucin, and consequently the viscosity [59], or the functional-
ization of nonviral vector formulations with mucolytic agents.
4.2. Intracellular barriers
Once extracellular barriers are overcome, there is still a long way full of hurdles before reaching 
the nucleus of target cells. Firstly, complexes carrying the genetic material need to be endocy-
tosed by target cells. The interaction between complexes and cell membranes can occur in an 
unspecific way or can be mediated by a specific ligand, which is the preferred one, especially 
for in vivo applications [60]. Of note, the choice of ligand to be incorporated into the nanopar-
ticle formulation depends not only on the target cell but also on the type of cell entry pathway 
that will be used once the ligand binds to the desired receptor.
Classically, there are four main pathways of endocytosis: clathrin-mediated endocytosis 
(CME), caveolae-mediated endocytosis (CVME), phagocytosis, and macropinocytosis [61, 62]. 
CME is an energy-dependent mechanism widely studied and characterized [63]. Typically, 
this pathway is directly associated with lysosomes, where the genetic material needs to leave 
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such biological compartment quickly before being degraded by the acidic environment and 
the enzymes found in lysosomes [63]. To avoid this enzymatic degradation, some interest-
ing strategies can be used, such as the formation of pores in the endosome membrane by 
incorporation of amphiphilic cationic peptides. This creates strong internal tensions in the 
membrane and enhances the exit of endosome content through such pores [64]. Another strat-
egy is known as the “proton sponge effect,” where the low pH within the endosome allows 
the protonation of trapped compounds that have a large capacity to absorb protons from 
the medium (buffer effect). Such protonation causes an important entry of ions (H+ and Cl−) 
and water in the endosome, which produce a swelling effect and its rupture. This effect has 
been observed in some cationic polymers with high buffering capacity over a wide pH range 
[64]. In CVME, internalized molecules go to the caveosome instead of lysosome [61] avoiding 
lysosomal degradation; however, there is still ongoing debate, with some authors claiming 
that CVME can fuse with lysosomes [65].
Phagocytosis is a special type of endocytosis used mainly by macrophages, monocytes, neu-
trophils, and dendritic cells, although other cell types can also use this cellular entry pathway 
[61]. Endocytosis mediated by phagocytosis comprises the formation of membrane extensions 
with certain forms to capture particles generally greater than 1 μm. In contrast, for endocyto-
sis mediated by macropinocytosis, membrane extensions do not surround particles but form 
some kind of protuberances that finally fuse with the cytoplasmic membrane. In many cases, 
the physicochemical properties of nonviral vector-based nanoparticles, such as particle size, 
superficial charge, morphology, or polydispersity, directly influence the endocytosis mecha-
nism and consequently the transfection efficiency.
Once the DNA is released into the cytosol of cells, it must enter the nucleus to produce its 
effect. This is considered a significant barrier that nonviral vectors must overcome in order 
to mediate a good transfection efficiency. One commonly used strategy to enhance nuclear 
import of genetic material is to incorporate a nuclear localization signal (NLS), such as polyly-
sine or protamine [66]. NLS contains some amino acids that interact with some proteins of the 
cytoplasm known as importines. These importins enhance nuclear entry through the nuclear 
pore complex of the nuclear membrane through an energy-dependent mechanism [67].
5. Drug formulation
The airways seem to be the natural way to treat respiratory diseases and a good alterna-
tive to systemic and more invasive procedures. Currently, aerosolization is the prefered 
method of administration for airway targeting since it is a noninvasive route that induces 
little stress to patients. Moreover, high quantities of drug can be deposited directly and fast 
into the lungs, which circumvents the blood circulation and avoids the first-pass effect of the 
liver. However, the effectiveness of such approach strongly depends on the development 
of smart drug formulation strategies. One of the critical steps that need to be taken into 
account for a successful gene delivery approach by inhalation is the formulation of the drug 
molecules into an appropriate inhalable form with sufficient stability and adequate aerody-
namic properties [68]. Highly susceptible molecules, such as nucleic acid, require special 
attention when delivered by this route of administration. The physicochemical constraints 
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such as the hydrodynamic shear forces generated during aerosolization can induce degrada-
tion of the nucleic acids, which will be more or less important depending on their size [69, 
70]. Therefore, the need to develop a suitable formulation able to protect the material from 
degradation and at the same time ensure delivery of nucleic acid to the target cells in the 
lung needs to be deeply considered. In this sense, the commonly accepted aerodynamic size 
for pulmonary gene delivery is within the range of 1–5 μm. Larger particles (4–7 μm) tend 
to deposit in the airways, while smaller particles (1–3 μm) and those in submicron range 
(<1 μm) reach the lower airways and deeper lung [68]. The aerodynamic diameter of a par-
ticle can be modified not only by changing its size but also by varying its density or shape, 
which opens new possible strategies for gene delivery to the lung, such as the design of large 
porous hollow particles [71].
Suitable formulations for pulmonary delivery are mainly prepared either by dissolving or 
by suspending the therapeutic molecules in a liquid or formulating them into a dry powder 
for inhalation using liquid inhalers (including nebulizers), dry powder inhalers (DPIs), or 
pressurized metered dose inhalers (pMDIs); each of them is suitable for different applications. 
Once the aerosolized droplets or microparticles are deposited next to the target location into 
the lungs, they need to dissolve in the lung lining fluid for subsequent absorption and cellular 
uptake [72]. Nowadays, viral gene delivery to the lungs is limited to liquid formulations using 
a nebulizer [36], and there is no dry powder or metered dose inhaler formulation available for 
any vector-drug combination. In most cases, the gene transfer efficiency to lung cells using 
viral vectors is still too low with traditional nebulizer devices, probably due to the degrada-
tion of viral envelope by the shear forces caused during aerosolization [73] and the viscous 
mucus found in obstructive diseases, like CF [74]. Moreover, and as previously highlighted, 
the use of adenoviral or AAV vectors would likely induce an acute immune response upon 
the initial administration or result in low efficacy following repeat dosing. This is particularly 
relevant since aerosolized gene therapy might require repeat dosing because mucus clear-
ance mechanisms and/or phagocytes may engulf and destroy the drug vector before it can 
be taken up by target cells [75]. In contrast, the simpler composition of nonviral vectors may 
have, in this case, an advantage over viral vectors, making readministration potentially more 
successful.
Although pulmonary gene-based therapies have not yet been granted marketing approval, 
numerous strategies are being tested both in vitro and in vivo, and various clinical trials are 
underway [19, 36]. Table 1 summarizes some of the strategies used to date for the pulmonary 
delivery of nucleic acids by aerosolization.
Nowadays, the most studied approach for gene delivery to the lung involves the nebuli-
zation of the selected formulation [76], turning it from a liquid solution to microdroplets. 
Depending on the aerosolization system used, such as jet, ultrasonic, or mesh nebulizers, the 
implemented hydrodynamic stress that the therapeutic molecules would be subject to varies 
[77]. Interestingly, several strategies have been studied to reduce the damage to the genetic 
material during the aerosolization process, by condensing the nucleic acids with positively 
charged molecules, such as polyethylenimine (PEI), protamine, or poly-L-lysine (PLL), among 
others [78].
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The elaboration of DPIs, composed of drug-based dry powders and an aerosol-generating 
device, also presents important advantages such as high physicochemical stability, easy han-
dling, and propellant-free aerosols. In order to transform the therapeutic nucleic acids into 
stable dry powders, several techniques, such as freeze-drying (FD) [79], spray-drying (SD) 
[80], and spray freeze-drying (SFD) [81], are being investigated. In addition, the incorpora-
tion of suitable stabilizing agents/thermal protectors such as polysaccharides (sucrose [79], 
trehalose [79], agarose [82], lactose [83], mannitol [81], or chitosan [84]), amino acids (leucine 
[84] or glycine [82]), or proteins (BSA [85]) is critical.
6. Commercialization
In addition to the above concerns, other relevant issues specifically related to the commercial-
ization of gene therapy medicinal products (GTMP) must also be considered. Commercially 
Description Vector Aerosolization References
In vivo aerosol delivery of 
PEI-DNA comp
PEI Nebulization [68]
Randomized, double-blind, 
placebo-controlled, Phase II 
trial in CF patients with mild 
lung disease
AAV2 viral Nebulization [32]
Nebulization of receptor-
targeted nanocomplexes for 
in vivo gene delivery to the 
airway epithelium
Receptor-
targeting 
peptides 
and cationic 
liposomes
Nebulization [69]
In vivo repeated aerosol 
delivery of pDNA/PEI 
complexes with CpG-free 
plasmids
PEI Nebulization or instillation [70]
In vivo aerosol delivery of 
DNA/liposomes to the lung
GL67A
cationic 
liposomes
Multiple nebulizers [71]
Randomized, double-blind, 
placebo-controlled, Phase 
IIb trial
GL67A cationic 
liposomes
Nebulization [14]
In vivo intratracheal 
administration of pDNA-
chitosan dry powders, 
obtained by SFD
Chitosan Dry powder, obtained by SFD, administered by 
intratracheal syringe
[72]
Dry powder aerosols for 
in vivo gene delivery to the 
lung
PEI Dry powder in insufflator lyophilization/
powderization with lactose, sucrose, or trehalose
[73]
Table 1. Pulmonary gene delivery strategies by aerosolization.
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available medical products based on gene therapy along with cell therapy and tissue engi-
neering are classified as advanced therapy medicinal products. Although highly promising, 
their translation into clinical practice is nowadays hampered by major critical issues such as 
complex regulatory and ethical aspects, along with the intrinsic difficulties to scale up these 
products to an industrial level [20].
Regarding the regulatory concerns of GTMP that affect clinical applications, the economical 
investments, along with their manufacture and control, demand more attention than chemi-
cally synthesized small molecules [86]. Therefore, a deep analysis of both costs and benefits 
needs to be done before considering the commercialization of such therapies [87].
Another relevant concern that jeopardizes the clinical use of GTMP in CF is the ethical aspect of 
clinical trials. Since the early 1990s, more than 25 Phase I gene therapy clinical trials have been 
conducted. These trials have been carried out largely to assess the safety and feasibility of gene 
transfer methods and their expression in the host, reporting variable successes for both viral 
and nonviral approaches. Gene therapy products designed for the treatment of CF must meet 
certain requirements in order to become a viable therapeutic option. For instance, their clinical 
efficacy must be demonstrated by analyzing appropriate variables of the lung function such as 
the patient´s vital capacity that they are able to expire in the first second of forced expiration 
(FEV1),  their age, sex or body composition, and the therapeutic efficacy which must be main-
tained with repeated administrations. In addition, the GTMP must demonstrate an acceptable 
profile when it comes to side effects, and other considerations such as treatment of early versus 
established lung disease must also be analysed.
Since a high percentage of patients affected by CF are children, clinical trials involving these 
patients must carefully balance the potential benefits of these therapies and the associated 
risks [88]. Regarding this controversial issue, the Gene Therapy Advisory Committee recom-
mends that clinical trials on children should only be performed under specific circumstances, 
whereby: (i) it has been demonstrated that the research is necessary to promote the health of 
the trial population, (ii) the research cannot be done in adults, and (iii) there is a high potential 
of therapeutic benefit [88]. In fact, owing to a demonstrated benefit of early gene therapy 
intervention, the age of enrolment of children in clinical trials has progressively reduced over 
the years from 18 to 12 years old. However, parents should have legal rights to make the final 
decision on behalf of their children.
Another critical hurdle that strongly compromises the clinical application of gene therapy 
products for the treatment of CF is the difficulty to scale up formulations that were origi-
nally developed for basic clinical research [89]. Most of these products are usually devel-
oped by small- and medium-sized enterprises, in collaboration with academic groups, 
which are usually highly engaged in preclinical activities, but have limited manufac-
turing experience at industrial level. For instance, the normal procedure for preparing 
nonviral-based gene therapy products is by simply mixing and pipetting the negatively 
charged genetic material and the positively charged polymer - or lipid-based nonviral 
vector formulations, which are often produced in the laboratory at small volumes that 
usually oscillate between 1 and 5 mL. However, the standardization of this procedure at 
industrial level to produce high and stable levels of complexes under GMP conditions 
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represents a great challenge that needs to be overcome for successful clinical application. 
In this sense, pilot plants, which employ small volumes of the product, represent an inter-
esting option to gain knowledge on the technical process before full scale up production.
7. Conclusion
Despite the fact that the CFTR gene was cloned two decades ago, the current, conven-
tional treatments for CF focus on masking the main symptoms, rather than addressing the 
underlying genetic cause of the disease. In this sense, gene therapy represents a promising 
alternative to tackle CF, considering the autosomal recessive nature of the most relevant 
ΔF508 mutation. Although the main objective of gene therapy seems simple, there are some 
hurdles that need to be overcome before gene therapy for CF becomes a realistic treat-
ment option. In any case, the increase in knowledge and recent advances in biopharma-
ceutical technology offer reasonable hope for the treatment of this devastating disease. The 
minicircle technology, along with the new gene editing tools, offer important advantages 
compared with classical plasmids used to add functional copies of the gene. Additionally, 
intense research in novel nonviral vectors functionalized to overcome both extra- and intra-
cellular barriers and the possibility to aerosolize such formulations without losing activity 
merit special attention.
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